Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
Phase 3positiveTEPEZZAPositive
AI Analysis
Summary
Amgen reported positive Phase 3 results demonstrating that subcutaneous TEPEZZA achieves IV-level efficacy in patients with moderate to severe thyroid eye disease, potentially expanding treatment options through improved delivery method.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Subcutaneous delivery showed IV-level efficacy in moderate to severe thyroid eye disease
Importance:8/10
Sentiment:
0.85
Phase 3positive datathyroid eye diseasesubcutaneousefficacy
Related Companies
Read the original article
Published by PharmaTimes on April 7, 2026 1:06 PM